本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 山东亚华电子股份有限公司（以下简称"公司"）于2025年4月19日在巨潮资讯网 （http://www.cninfo.com.cn）上披露了《2024年年度报告》（公告编号：2025-012）， 经自查发现《2024年年度报告》中"'第四节 公司治理'之'七、董事、监事和高级 管理人员情况'之'2、任职情况''3、董事、监事、高级管理人员报酬情况'"及 "'第四节 公司治理'之'十一、公司员工情况'之'2、薪酬政策'"中的非财务部 分内容有误，现对该部分内容予以更正，相关更正信息不影响公司报告期财务状况、 经营成果和现金流状况。具体更正如下： 证券代码：301337 证券简称：亚华电子 公告编号：2025-024 山东亚华电子股份有限公司 关于对2024年年度报告的补充更正公告 更正前： 在其他单位任职情况 适用 □不适用 | 任职人员姓名 | 其他单位名称 青岛白泽亚华科 | 在其他单位担任 的职务 执行董事兼总经 | 任期起始日期 | 任期终止日期 | 在其他单位是否 领取报酬津贴 | | --- | --- ...

Financial Performance - The net profit attributable to shareholders for the reporting period was -26,486,052.99 RMB, a decrease of 158.19% compared to the same period last year[4]. - The company's operating revenue for 2024 was ¥217,910,015.34, a decrease of 37.97% compared to ¥351,310,084.13 in 2023[23]. - The net profit attributable to shareholders for 2024 was -¥26,486,052.99, representing a decline of 158.19% from ¥45,516,763.94 in 2023[23]. - The net cash flow from operating activities for 2024 was -¥50,334,778.04, a significant decrease of 531.51% compared to -¥7,970,508.38 in 2023[23]. - The basic earnings per share for 2024 was -¥0.25, down 151.02% from ¥0.49 in 2023[23]. - Total assets at the end of 2024 were ¥1,223,315,775.74, a decrease of 5.37% from ¥1,292,728,742.95 at the end of 2023[23]. - The net assets attributable to shareholders at the end of 2024 were ¥1,102,557,347.73, down 3.90% from ¥1,147,259,504.01 at the end of 2023[23]. - Total revenue for 2024 was ¥217,910,015.34, a decrease of 37.97% compared to ¥351,310,084.13 in 2023[88]. - Revenue from hospital intelligent communication systems was ¥215,745,562.86, down 38.40% from ¥350,237,733.77 in the previous year[88]. - The domestic market contributed ¥211,207,767.02, representing 96.92% of total revenue, a decline of 39.22% year-over-year[88]. - The overseas market saw an increase of 76.79%, generating ¥6,702,248.32 compared to ¥3,791,176.74 in 2023[88]. - Gross profit margin for hospital intelligent communication systems was 38.89%, down 6.94% from the previous year[92]. Market Strategy and Expansion - The company aims to consolidate its domestic market while actively investing in overseas market expansion to explore new growth opportunities[4]. - The company plans to maintain investment in new technologies to enhance product competitiveness and seize opportunities in the medical field for renovation projects[4]. - The company is focusing on integrating mobile nursing products with smart ward systems to enhance product competitiveness and increase main revenue[102]. - The company is advancing the development of a new generation of surgical behavior management products based on existing project experience to improve competitiveness in the market[103]. - The company is positioned to benefit from government policies promoting the integration of new generation information technology in elderly care, with plans to establish over 100 standard-compliant smart nursing homes in Shandong Province by the end of 2025[37]. - The company is actively involved in the development of smart hospital solutions, including smart wards and smart outpatient services, which enhance medical resource utilization and management efficiency[35]. - The company is focusing on strategic planning, market expansion, product development, and internal control to adapt to global economic changes and industry competition[145]. Research and Development - The company is focusing on the integration of artificial intelligence, big data, and cloud computing in its operations to improve efficiency and service quality in the healthcare sector[37]. - The company plans to increase R&D investment to create integrated solutions that enhance clinical and management value in hospitals[74]. - R&D investment as a percentage of operating revenue increased to 18.92% in 2024 from 13.48% in 2023[103]. - The number of R&D personnel decreased by 16.41% to 163 in 2024 from 195 in 2023[103]. - The company has accumulated a total of 153 authorized patents and 242 software copyrights as of December 31, 2024, reflecting its commitment to innovation and technology advancement[71]. - The company emphasizes technological innovation, having developed core technologies such as modular nursing communication control technology and high-bandwidth networking solutions[42]. Operational Challenges - The company is facing intensified industry competition and delayed market demand release, impacting revenue expectations[4]. - The main products are experiencing a downward trend in market prices, leading to a decline in overall gross profit margin[4]. - The company acknowledges the risks associated with future plans and encourages investors to be aware of these risks[5]. - The company has not identified any significant risks to its ongoing operations as of the report date[4]. - The company faces seasonal risks due to the nature of hospital procurement processes, which may lead to uneven revenue distribution throughout the year[144]. Governance and Management - The company has established a governance structure in compliance with relevant laws and regulations, ensuring independent operations from its controlling shareholder[151][159]. - The board of directors consists of 9 members, including 3 independent directors, and has held 6 meetings during the reporting period[153]. - The company has implemented a performance evaluation system for senior management that combines quantitative and qualitative assessments, linking compensation to responsibilities and contributions[156]. - The company maintains effective communication with stakeholders, emphasizing social responsibility and balancing interests among various parties[157]. - The company is committed to enhancing its internal control management and improving the overall quality of its management team[145]. Investment and Funding - The company has raised a total of CNY 84,923.00 million through its public offering, with a net amount of CNY 78,253.78 million after deducting fees[122]. - As of December 31, 2024, the company has utilized CNY 38,113.21 million of the raised funds, with CNY 40,069.02 million remaining unutilized[122]. - The company has allocated CNY 25,800 million of the raised funds to permanently supplement working capital and CNY 1,000 million to repay bank loans[122]. - The company has reported a total investment of CNY 3,922,613.75 during the reporting period, marking a 100% increase compared to the previous year[117]. - The company has not reported any issues or problems regarding the use and disclosure of raised funds[125]. Employee and Training - The total number of employees at the end of the reporting period is 604, with 509 in the parent company and 95 in major subsidiaries[189]. - The company organized over 10 large training events in 2024, with more than 300 employees participating, significantly enhancing team skills and corporate culture awareness[192]. - The company provides a comprehensive benefits package, including holiday bonuses, regular health check-ups, commercial insurance, mutual aid funds, and birthday care[191]. - The company has a competitive salary standard based on industry levels, company performance, job value, and regional differences[191]. Profit Distribution Policy - The company emphasizes cash dividends as the primary form of profit distribution, ensuring a minimum of 10% of the distributable profit is allocated as cash dividends[197]. - The cumulative cash dividends over the three-year planning period should not be less than 30% of the average annual distributable profit[197]. - In mature stages without major capital expenditures, the cash dividend proportion should be at least 80% of the profit distribution[200]. - In growth stages with major capital expenditures, the cash dividend proportion should be at least 20%[200]. - The company allows shareholders, independent directors, and public investors to propose suggestions and supervise the dividend policy[198].

Market Performance - The Shanghai Composite Index and Shenzhen Component Index experienced declines of 0.30% and 0.69% respectively on May 5, 2025, while the ChiNext Index and STAR Market 50 fell by 0.87% and 1.96% respectively [1] - Among 33 A-share companies in Zibo, 30 saw an increase, 1 remained flat, and 2 declined during the same period [1] Notable Stock Movements - Weiming Pharmaceutical (002581) achieved a remarkable 23.29% increase over five days, leading the gains [1] - Yahua Electronics (301337) and Jincheng Pharmaceutical (300233) also saw significant increases of 17.30% and 11.31% respectively [1] - On May 7, PEEK material concept stocks surged, with Zhongxin Fluorine Materials (002915) hitting the daily limit for the sixth time in nine days, and Kaisheng New Materials (301069) rising by 2.29% with a trading volume of 4.02 billion yuan [1] Company Announcements - Kehui Co., Ltd. announced a share repurchase plan with a budget between 9 million and 16 million yuan, with a maximum repurchase price of 17 yuan per share, aimed at employee stock ownership plans [1] Financial Results - Furuida (600223) reported a revenue of 526 million yuan in its cosmetics segment for Q1 2025, with a gross margin of 61.06% [3] - Qichang Tenda (002408) achieved total revenue of 5.618 billion yuan in Q1 2025, a year-on-year increase of 2.53%, but saw a significant drop in net profit by 83.18% to 5.4007 million yuan [3] - Xinhua Medical (600587) reported a total revenue of 2.308 billion yuan, down 8.74% year-on-year, with a net profit decline of 23.97% to 160 million yuan [3] - Bohui Paper (600966) reported a total revenue of 4.564 billion yuan, a 3.77% increase year-on-year, but a net profit decline of 46.91% to 53.3737 million yuan [3] Market Capitalization - In terms of market capitalization, Yingke Medical (300677) led with 14.708 billion yuan, followed closely by Shandong Pharmaceutical Glass (600529) at 14.626 billion yuan, and Qichang Tenda (002408) at 12.963 billion yuan [4]

北京德和衡律师事务所 BEIJING DHH LAW FIRM 北京德和衡律师事务所 关于山东亚华电子股份有限公司 2024年年度股东大会的 法律意见书 德和衡证见意见（2025）第67号 中国·北京市朝阳区建国门外大街 2 号银泰中心 C 座 11、12 层 电话： (+86 10) 8540 7666 邮编：100022 www.deheheng.com 北京德和衡律师事务所 关于山东亚华电子股份有限公司 2024年年度股东大会的 法律意见书 德和衡证见意见（2025）第67号 本法律意见书仅供贵公司为本次股东大会之目的而使用，不得用于其他任何目的。本所律 师同意贵公司将本法律意见书随贵公司本次股东大会其他信息披露材料一并向公众披露，并依 法对本法律意见书承担相应责任。 本所律师根据对事实的了解以及对中国现行法律、法规和规范性文件的理解，按照律师行 业公认的业务标准、道德规范和勤勉尽责精神，现出具法律意见如下： 一、 本次股东大会的召集与召开程序 致：山东亚华电子股份有限公司 北京德和衡律师事务所（以下简称"本所"）接受山东亚华电子股份有限公司（以下简称 "公司"或"贵公司"）的委托，指派本所律师出席贵公 ...

证券代码：301337 证券简称：亚华电子 公告编号：2025-023 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 5 月 9 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00；通 过深圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的具体时间为： 2025 年 5 月 9 日 9:15-15:00。 山东亚华电子股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 1、 本次股东大会不存在否决议案的情形。 2、 本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、 召开时间： （1）现场会议召开时间：2025 年 5 月 9 日（星期五）14:00 2、 现场会议召开地点：淄博市高新区青龙山路 9509 号山东亚华电子股份有 限公司会议室 3、 召开方式：现场结合网络 4、 召集人：董事会 5、 主持人：董事长耿斌先生 6、 本次会议的召集、召开符合《中华人民共和国公司法 ...

证券代码：301337 证券简称：亚华电子 投资者关系活动记录表 投资者关系活动类别 ☐特定对象调研 ☐分析师会议 ☐媒体采访 业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 ☐其他（请文字说明其他活动内容） 参与单位名称及人员姓名 线上参与公司2024年度网上业绩说明会的投资者 时间 2025年05月08日 15:00-16:00 地点 价值在线（https://www.ir-online.cn/）网络互动 上市公司接待人员姓名 实控人、董事长 耿斌 董事、总经理 向晖 独立董事 吴忠堂 财务总监、董事会秘书 于雷 投资者关系活动主要内容 介绍 1.公司提到将把握医疗领域旧病房更新改造的政策机遇，具体 有哪些项目已经启动或正在规划中？ 答:根据国务院《推动大规模设备更新和消费品以旧换新行动 方案》要求：加强优质高效医疗卫生服务体系建设，推进医疗卫生 机构装备和信息化设施迭代升级……推动医疗机构病房改造提升， 补齐病房环境与设施短板。公司"IP两线组网"技术，凭借"可靠 +便捷施工"双擎，切实为旧病房改造项目提供更优落地方案。截 至目前，上海第一人民医院、大同市第五人民医院、海南医科大学 第二附属医院等项目 ...

东吴证券股份有限公司 关于山东亚华电子股份有限公司 2024 年度持续督导跟踪报告 | 保荐人名称：东吴证券股份有限公司 | 被保荐公司简称：亚华电子 | | --- | --- | | 保荐代表人姓名：曹飞 | 联系电话：0512-62938583 | | 保荐代表人姓名：庞家兴 | 联系电话：0512-62938583 | 一、保荐工作概述 | 报告事项 | 说明 | | --- | --- | | 1.保荐代表人变更及其理由 | 无 | | 2.报告期内中国证监会和深圳证券交易所对保荐 | 报告期内不存在中国证监会和深交所对本项目发 | | 人或者其保荐的公司采取监管措施的事项及整改 | 行人或因本项目对保荐机构采取监管措施的事项 | | 情况 | 及整改情况。 | | 3.其他需要报告的重大事项 | 无 | （以下无正文） | （2）现场检查报告是否按照本所规定报送 | 是 | | --- | --- | | （3）现场检查发现的主要问题及整改情况 | 不适用 | | 6.发表专项意见情况 | | | （1）发表专项意见次数 | 8 次 | | （2）发表非同意意见所涉问题及结论意见 | 不适用 | ...

Overall Overview - In Q1 2025, the company achieved total operating revenue of 39.57 million yuan, a year-on-year increase of 30.01% [1] - The net profit attributable to the parent company was -5.94 million yuan, a year-on-year increase of 28.0% [1] - The net profit after deducting non-recurring gains and losses was -6.20 million yuan, a year-on-year increase of 29.65% [1] Profitability - The company's gross profit margin reached 40.38%, an increase of 22.34 percentage points year-on-year [2] - The net profit margin was -16.63%, an increase of 38.65 percentage points year-on-year, indicating improved cost control and higher added value of products or services [2] Expense Control - Total sales, management, and financial expenses amounted to 13.98 million yuan, accounting for 35.33% of operating revenue, a decrease of 12.34 percentage points compared to the same period last year [3] Cash Flow and Debt Situation - Operating cash flow per share improved from -0.27 yuan to -0.09 yuan, a year-on-year increase of 65.37%, but remained negative [4] - Cash and cash equivalents decreased from 732 million yuan to 517 million yuan, a reduction of 29.39% [4] - Interest-bearing debt decreased from 6.78 million yuan to 4.41 million yuan, a decrease of 34.90% [4] Other Key Indicators - Net asset per share decreased from 10.93 yuan to 10.52 yuan, a year-on-year decrease of 3.77% [5] - Earnings per share improved from -0.08 yuan to -0.06 yuan, a year-on-year increase of 25.00% [5]

证券代码：301337 证券简称：亚华电子 公告编号：2025-022 山东亚华电子股份有限公司 关于举办2024年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 山东亚华电子股份有限公司（以下简称"公司"）于2025年4月19日在巨潮资讯网 （www.cninfo.com.cn）披露了《2024年年度报告》及《2024年年度报告摘要》。为便 于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于2025年5 月8日（星期四）15:00-16:00在"价值在线"（www.ir-online.cn）平台举办公司 2024年度网上业绩说明会（以下简称"业绩说明会"），与投资者进行沟通和交流， 广泛听取投资者的意见和建议。现将有关事项公告如下： 一、业绩说明会召开的时间、地点和方式 召开时间：2025年5月8日（星期四）15:00-16:00 召开地点：价值在线（www.ir-online.cn） 召开方式：网络互动方式 二、业绩说明会出席人员 公司实控人、董事长耿斌先生，董事、总经理向晖女士，独立董事吴忠堂先生， 财务总监、董 ...

证券代码：301337 证券简称：亚华电子 公告编号：2025-021 山东亚华电子股份有限公司 关于2025年第一季度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 山东亚华电子股份有限公司（以下简称"公司"）根据《企业会计准则》《深圳 证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号— —创业板上市公司规范运作》等相关规定的要求，基于谨慎性原则，为了更加真实、 准确的反映公司的资产与财务状况，公司及子公司于2025年第一季度末对应收款项、 存货、固定资产、在建工程等资产进行了全面清查，并对存在可能发生减值迹象的金 融资产在整个存续期内的预期信用损失、各类存货的可变现净值、固定资产、在建工 程等资产的可收回金额进行了充分的分析和评估，在此基础上对发生资产减值损失的 资产计提减值准备。经测算，2025年第一季度公司计提减值损失3,021,146.23元，具 体情况如下： | | 单位：元 | | --- | --- | | 1、信用减值损失 | -1,308,046.50 | | 其中：应收账款坏账损失 | -1 ...